Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXT007 new preparation method clinical pharmacology study in healthy Japanese adult men
jRCT2031220050Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of zemocimig in hemophilia A, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Plasma NXT007 levels, Activated partial thromboplastin time and 7 more. Started May 2022; status: completed.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2031220050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220050.